Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor‐α and melphalan for limb‐threatening soft tissue sarcoma
Dirk J. Grünhagen(Erasmus MC), Alexander M.M. Eggermont(University Medical Center Utrecht), Albertus N. van Geel, Cornelis Verhoef(Erasmus MC Cancer Institute), Wilfried J. Graveland(Erasmus MC Cancer Institute), Johannes H. W. de Wilt(Radboud University Nijmegen)
Cited by 137
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k